WST Stock Overview
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
West Pharmaceutical Services Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$246.39|
|52 Week High||US$475.00|
|52 Week Low||US$244.71|
|1 Month Change||-18.89%|
|3 Month Change||-17.74%|
|1 Year Change||-42.36%|
|3 Year Change||76.40%|
|5 Year Change||160.40%|
|Change since IPO||5,121.51%|
Recent News & Updates
Is West Pharmaceutical Services, Inc. (NYSE:WST) Expensive For A Reason? A Look At Its Intrinsic Value
Does the September share price for West Pharmaceutical Services, Inc. ( NYSE:WST ) reflect what it's really worth...
Is There Now An Opportunity In West Pharmaceutical Services, Inc. (NYSE:WST)?
Today we're going to take a look at the well-established West Pharmaceutical Services, Inc. ( NYSE:WST ). The company's...
Do West Pharmaceutical Services' (NYSE:WST) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
|WST||US Life Sciences||US Market|
Return vs Industry: WST underperformed the US Life Sciences industry which returned -34.2% over the past year.
Return vs Market: WST underperformed the US Market which returned -23.7% over the past year.
|WST Average Weekly Movement||5.1%|
|Life Sciences Industry Average Movement||9.7%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: WST is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: WST's weekly volatility (5%) has been stable over the past year.
About the Company
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components.
West Pharmaceutical Services Fundamentals Summary
|WST fundamental statistics|
Is WST overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|WST income statement (TTM)|
|Cost of Revenue||US$1.73b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||9.26|
|Net Profit Margin||23.41%|
How did WST perform over the long term?See historical performance and comparison
0.3%Current Dividend Yield
Is WST undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for WST?
Other financial metrics that can be useful for relative valuation.
|What is WST's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does WST's PE Ratio compare to its peers?
|WST PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
MTD Mettler-Toledo International
WST West Pharmaceutical Services
Price-To-Earnings vs Peers: WST is expensive based on its Price-To-Earnings Ratio (26.6x) compared to the peer average (24.8x).
Price to Earnings Ratio vs Industry
How does WST's PE Ratio compare vs other companies in the US Life Sciences Industry?
Price-To-Earnings vs Industry: WST is expensive based on its Price-To-Earnings Ratio (26.6x) compared to the US Life Sciences industry average (25.3x)
Price to Earnings Ratio vs Fair Ratio
What is WST's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||26.6x|
|Fair PE Ratio||24.2x|
Price-To-Earnings vs Fair Ratio: WST is expensive based on its Price-To-Earnings Ratio (26.6x) compared to the estimated Fair Price-To-Earnings Ratio (24.2x).
Share Price vs Fair Value
What is the Fair Price of WST when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: WST ($246.39) is trading above our estimate of fair value ($245.56)
Significantly Below Fair Value: WST is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is West Pharmaceutical Services forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: WST's forecast earnings growth (9% per year) is above the savings rate (1.9%).
Earnings vs Market: WST's earnings (9% per year) are forecast to grow slower than the US market (14.7% per year).
High Growth Earnings: WST's earnings are forecast to grow, but not significantly.
Revenue vs Market: WST's revenue (7.3% per year) is forecast to grow slower than the US market (7.6% per year).
High Growth Revenue: WST's revenue (7.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: WST's Return on Equity is forecast to be low in 3 years time (19.2%).
Discover growth companies
How has West Pharmaceutical Services performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: WST has high quality earnings.
Growing Profit Margin: WST's current net profit margins (23.4%) are higher than last year (20.6%).
Past Earnings Growth Analysis
Earnings Trend: WST's earnings have grown significantly by 34.2% per year over the past 5 years.
Accelerating Growth: WST's earnings growth over the past year (32%) is below its 5-year average (34.2% per year).
Earnings vs Industry: WST earnings growth over the past year (32%) exceeded the Life Sciences industry 15.6%.
Return on Equity
High ROE: WST's Return on Equity (28.3%) is considered high.
Discover strong past performing companies
How is West Pharmaceutical Services's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: WST's short term assets ($1.8B) exceed its short term liabilities ($565.1M).
Long Term Liabilities: WST's short term assets ($1.8B) exceed its long term liabilities ($372.2M).
Debt to Equity History and Analysis
Debt Level: WST has more cash than its total debt.
Reducing Debt: WST's debt to equity ratio has reduced from 18% to 10.4% over the past 5 years.
Debt Coverage: WST's debt is well covered by operating cash flow (267.9%).
Interest Coverage: WST's interest payments on its debt are well covered by EBIT (112.7x coverage).
Discover healthy companies
What is West Pharmaceutical Services's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
|West Pharmaceutical Services Dividend Yield vs Market|
|Company (West Pharmaceutical Services)||0.3%|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Life Sciences)||0.3%|
|Analyst forecast in 3 Years (West Pharmaceutical Services)||0.3%|
Notable Dividend: WST's dividend (0.29%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.67%).
High Dividend: WST's dividend (0.29%) is low compared to the top 25% of dividend payers in the US market (4.68%).
Stability and Growth of Payments
Stable Dividend: WST is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: WST is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: WST is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: WST is not paying a notable dividend for the US market.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Eric Green (52 yo)
Mr. Eric M. Green has been the Chief Executive Officer of West Pharmaceutical Services, Inc. since April 24, 2015 and its President since December 2015. He has been a Director of West Pharmaceutical Servic...
CEO Compensation Analysis
|Eric Green's Compensation vs West Pharmaceutical Services Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$9m||US$1m|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$8m||US$989k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$7m||US$936k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$5m||US$880k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$5m||US$824k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$4m||US$749k|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||US$8m||US$474k|
Compensation vs Market: Eric's total compensation ($USD9.47M) is about average for companies of similar size in the US market ($USD13.05M).
Compensation vs Earnings: Eric's compensation has increased by more than 20% in the past year.
Experienced Management: WST's management team is considered experienced (2.9 years average tenure).
Experienced Board: WST's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: WST insiders have only sold shares in the past 3 months.
Recent Insider Transactions
|02 Aug 22||SellUS$4,836,074||Bernard Birkett||Individual||14,174||US$343.38|
|01 Aug 22||SellUS$1,848,306||Silji Abraham||Individual||5,374||US$343.93|
|Owner Type||Number of Shares||Ownership Percentage|
|State or Government||32,767||0.04%|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
West Pharmaceutical Services, Inc.'s employee growth, exchange listings and data sources
- Name: West Pharmaceutical Services, Inc.
- Ticker: WST
- Exchange: NYSE
- Founded: 1923
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$18.245b
- Shares outstanding: 74.05m
- Website: https://www.westpharma.com
Number of Employees
- West Pharmaceutical Services, Inc.
- 530 Herman O. West Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|WST||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Dec 1972|
|WPS||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 1972|
|WPS||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Dec 1972|
|WST *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Dec 1972|
|W2ST34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 35 REPR 1 COM USD0.25||BR||BRL||Aug 2021|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/27 00:00|
|End of Day Share Price||2022/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.